Key Highlights
- Abingdon Health shares rose close to 5% with no fresh announcement, continuing a gradual reappraisal of the stock.
- Full-year Revenue to 30 June 2026 is expected at about £11.3m, up 31% on the prior year.
- The company progressed to adjusted EBITDA profitability in the second half of the year.
- Two CDMO contracts worth a combined $2.5m and £4.8m underpin the FY27 growth pipeline.
- Cash stood at £2.9m at year-end, following a £3.2m placing to fund US Manufacturing expansion.
The York-based lateral-flow specialist has spent the past year rebuilding itself around contract development and manufacturing. After a trading update pointing to 31% revenue growth and a maiden move into second-half profitability, investors are weighing whether the momentum can carry into a bigger FY27.
A quiet gain in a thinly traded micro-cap
Shares in Abingdon Health (LSE:ABDX), the AIM-quoted rapid-diagnostics company, edged higher in the latest session, adding close to 5% in a move that owed more to the accumulated weight of recent news than to any single announcement on the day. There was no fresh regulatory filing or trading statement to obviously account for the rise, and in a stock as thinly traded as Abingdon a modest amount of buying can move the price several points.
The move comes as investors continue to digest a run of updates that have gradually reshaped the Investment case. Abingdon spent its early listed life as a Covid-era antibody-test name, and the collapse of that market left the shares as a Penny Stock trading well below their 2020 flotation price. What has changed is the pivot to a contract development and manufacturing organisation, or CDMO, model — designing and making lateral-flow tests for other companies rather than relying on its own branded products.
Latest developments
The most recent substantive news came on 29 July 2026, when Abingdon issued a trading update covering the year to 30 June 2026. The company said it expected to report total revenue of about £11.3m, up 31% on the £8.6m recorded in FY25, and — importantly — that it had progressed to adjusted EBITDA profitability in the second half. Executive chairman Dr Chris Hand said the group was 'delighted to announce revenue growth of over 30% and a move into adjusted EBITDA profitability in the second half of the year'.
That followed two contract wins earlier in 2026 that underpin the CDMO story. On 12 March the company announced a contract worth around US$2.5m with a UK-based customer to develop a clinical self-test, a phased 18-month programme with most revenue expected in FY27. Weeks later, on 30 March, it disclosed lateral-flow contracts worth a combined £4.8m with a US-based customer covering development and manufacturing scale-up of multiplex quantitative assays over roughly 27 months. That second announcement drove the shares up more than 13% on the day.
Full audited results for FY26 are expected in early October 2026, with detailed FY27 guidance to accompany them. For now, the July update remains the freshest anchor point for the shares.
The financial and operational picture
Abingdon's numbers are those of a Business still in transition rather than one that has arrived. Half-year revenue for the six months to 31 December 2025 came in at £4.5m, up 45% year on year, and the expected 63% jump in second-half revenue points to accelerating workload as contracted programmes ramp up. The shift into adjusted EBITDA profitability in H2 is a genuine milestone for a group that has reported losses since the pandemic-era boom faded.
The projected £11.3m outturn does, however, sit below the £12.6m the company was guiding towards in January, a reminder that revenue recognition on development contracts can be lumpy. Management flagged that roughly £0.5m of reader-instrument sales slipped out of the second half, and that expected revenue from the Find Out From Home consumer-testing Partnership had moved into FY27 as that customer worked through its own fundraising. For a business of this size, timing slippage of that order is material even when the underlying pipeline is intact.
On the balance sheet, Abingdon ended June 2026 with £2.9m of cash, up from £1.9m a year earlier, having raised £3.2m net in an October 2025 placing earmarked for US manufacturing expansion and working capital. Reaching second-half EBITDA profitability eases the pressure on that cash pile, but £2.9m is not a deep cushion for a company simultaneously investing in its Abingdon Analytical laboratory arm and building out US manufacturing. Cash runway and working-capital discipline therefore remain central, particularly as larger multi-year contracts consume resources up front before revenue is recognised.
What could drive the shares next
The clearest potential catalyst is the FY26 results in early October, and specifically the FY27 guidance that comes with them. Management has repeatedly pointed to the CDMO contracts signed during FY26 as the foundation for 'significant revenue growth' in FY27, and investors will look for that ambition to be quantified, and for confirmation that the US$2.5m and £4.8m programmes are converting into recognised revenue on schedule.
Beyond the confirmed contracts, further CDMO wins would matter. Abingdon's pitch is full programme management — taking a client from feasibility and regulatory pathway through to manufacturing and multi-territory approvals — and each new deal adds Backlog while reinforcing that end-to-end proposition. The potential to be appointed 'legal manufacturer' on the US programme, referenced in March, hints at longer-term, higher-value manufacturing revenue if the development phases complete successfully.
Risks investors should watch
The risks are those common to sub-scale AIM diagnostics names, and they are real. Revenue remains concentrated in a small number of contracts, so the delay or loss of any one programme has an outsized effect — as the FY26 shortfall against earlier guidance already demonstrated. Development-stage contracts are milestone-driven, and clients' own timelines, funding and regulatory progress are largely outside Abingdon's control.
Liquidity in the shares is thin and the price is volatile, which cuts both ways: the same lack of depth that can lift the stock on light buying can amplify declines just as easily. With £2.9m of cash and continued investment in US manufacturing, a further fundraise cannot be dismissed if growth requires more Working Capital than internal Cash Flow can supply, and any placing would risk diluting existing holders. Adjusted EBITDA profitability, while encouraging, is not the same as sustained statutory profit or free cash flow.
Investor takeaway
Abingdon Health (LSE:ABDX) has done the hard part of reinventing itself: revenue is growing at a 30%-plus clip, the second half tipped into adjusted EBITDA profitability, and a pair of multi-year contracts give the CDMO narrative some substance. The latest gain looks less like a response to specific news and more like positioning ahead of October's results, when FY27 guidance should show whether the contract book translates into the growth management keeps flagging.
The counterweight is a modest cash balance, lumpy contract-driven revenue that has already undershot earlier guidance once, and a register exposed to the swings of a thinly traded micro-cap. Investors will be watching the October results, the pace at which the signed US and UK contracts convert to revenue, and any sign of fresh wins or funding needs. The pivot is credible; the proof will be in whether FY27 delivers on the promise the contracts imply.






Please wait processing your request...